Conceivable Life Sciences

Conceivable Life Sciences has developed AURA, the world's first AI-powered automated IVF laboratory. This innovative system aims to enhance the accessibility, efficiency, and success of fertility treatments. With approximately 1 in 6 people facing infertility globally, AURA addresses a significant gap in reproductive healthcare by streamlining IVF processes through automation. AURA integrates six workstations to perform essential IVF lab functions, including sperm processing, egg preparation, and incubation. The system utilizes AI, robotics, and advanced optics to ensure precision and consistency in microscopic procedures. Conceivable's technology not only improves outcomes but also enhances traceability and reduces costs for clinical partners. The company is currently conducting a 100-patient pilot study, with early results indicating positive outcomes. Conceivable has secured $50 million in Series A funding to support its U.S. launch in 2026 and plans to expand partnerships with fertility networks. Its mission is to become the lab of choice for IVF operators, helping more individuals achieve their dream of parenthood.